HDL therapies — past, present and future
Journal Title: Journal of Medicines Development Sciences - Year 2015, Vol 1, Issue 2
Abstract
For a number of years, high-density lipoprotein (HDL) has been recognized to have an athero-protective role by promoting reverse lipid transport, a process facilitating the cholesterol efflux from atherosclerotic plaques in the artery wall and its elimination by the liver via biliary excretion. On the contrary, low-density lipoprotein (LDL) particles carry cholesterol to the organs and tissues where it can be used to produce hormones or maintain cell metabolism. When an imbalance develops, as a result of either an excess level of cholesterol associated with LDL (LDL-C) or a less effective cholesterol elimination by HDL (HDL-C), this causes an excess of cholesterol to be transported to the tissues and promotes the deposition of cholesterol. This often occurs in the artery walls, particularly in the coronary arteries. There is no approved medical treatment for directly suppressing or treating the atherosclerotic plaque once it is formed. Epidemiological studies have shown that the risk of developing cardio-vascular disease (CVD) is higher in patients with low levels of HDL-C regardless of LDL-C levels, even in patients optimally treated with LDL-C-lowering therapies. These data highlight that low HDL-C and low HDL particle number is an important target of therapies aiming to reduce the residual risk of CVD.
Authors and Affiliations
Ronald Barbaras
Keywords
Related Articles
- EP ID EP679248
- DOI -
- Views 238
- Downloads 0
The Association for the Accreditation of Human Research Protection Programs: 15 years of emphasizing research safety, ethics, and quality
This year marks the 15th anniversary of the founding of the Association for the Accreditation of Human Research Protection Programs (AAHRPP), an organization that has been instrumental in strengthening protections for re...
Models for accessing biomedical innovation in Asia
Asian countries are striving to transition into innovation-driven economies, and healthcare is a key sector on government agendas. Strong funding at academic institutions, high-impact publications, state-of-the-art clini...
Brazil is gaining its momentum in pharmaceutical development
Brazil is one of the world’s largest economies and pharmaceutical markets, having the Brazilian government as an important purchaser. There are strong local companies that have grown sustainably after the introduction of...
The Faculty of Pharmaceutical Medicine – Foundation, function and future
The Faculty of Pharmaceutical Medicine was established in the United Kingdom (UK) in 1989 to develop and maintain competence, ethics and the highest professional standards of practice in the discipline. This article char...
Open innovation to bolster research and development for neglected and emerging infectious diseases
Infections remain a significant cause of disease, disability, and death in developing countries. Unfortunately, many of these infections, including centuries-old neglected diseases such as malaria and newly emerging and...